Whalesbook
Alkem Laboratories has received an income tax assessment order for Assessment Year 2023-24, disputing tax liabilities totaling ₹333.38 crore. The pharmaceutical company confirmed it plans to appeal the order.
The dispute stems from the disallowance of a portion of a deduction claimed under Section 80IE and additions related to transfer pricing adjustments, which concern the pricing of goods and services between related entities.
Alkem Laboratories stated that no payment is expected due to the utilization of Minimum Alternate Tax (MAT) credit, a tax credit available to companies paying a minimum tax. Consequently, the company anticipates no material financial or operational impact from the demand, asserting the grounds for dispute are not tenable.
Despite Alkem's confidence, a significant disputed tax amount can still represent an overhang. Successful appeals are crucial to prevent potential future cash outflows and protect reported profitability. The company will commit resources to the appeal process, meaning shareholders may face uncertainty regarding the final tax outcome. An adverse ruling could necessitate re-evaluating tax provisions and impact future earnings per share.
Such tax challenges, including disputes over transfer pricing and deductions, are common for large pharmaceutical firms. Peers like Dr. Reddy's Laboratories and Sun Pharmaceutical Industries have also navigated similar assessments, indicating these are part of the sector's operating landscape.
Alkem Laboratories' financial performance shows revenue grew at a Compound Annual Growth Rate (CAGR) of 8.5% from FY22 to FY25 on a consolidated basis. The company reported a Net Profit Margin of 12.1% for FY25 on a consolidated basis and maintained a Debt/Equity Ratio of 0.3 as of Q4 FY25 on a consolidated basis.
Investors will monitor the progress and outcome of Alkem's appeal. Any further communications from tax authorities or the company, and commentary on tax matters during future earnings calls, will be closely watched.